{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:54:55Z","timestamp":1794002095635,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Intravesical bacillus Calmette-Gu\u00e9rin (BCG) therapy reduces recurrence in non-muscle invasive bladder cancer (NMIBC). Various scoring models have been developed to predict recurrence, and this study aims to improve them by analyzing hematologic parameters and urinary immune cells. This study involved 88 bladder cancer patients treated with BCG between January 2022 and January 2023. Preoperative hematological parameters were recorded from two separate blood samples. Urine samples were collected before and after the first and sixth BCG instillations and analyzed by flow cytometry to determine the proportions of T cells, neutrophils, and myeloid-derived suppressor cells (MDSCs). Results were compared based on recurrence status and within-group changes. Six patients died from non-cancer causes, and five were excluded due to irregular follow-ups or external monitoring. Of the remaining 77 patients, followed for an average of 30 months, 12 experienced recurrence, and 65 did not. No significant differences were found in clinical or histopathological factors. Urine analysis revealed a higher Neutrophil\/T cell ratio in patients with recurrence, while the T\/MDSCs ratio increased significantly in the non-recurrent group post-BCG. Additionally, the MDSCs\/Total Cell ratio significantly decreased post-treatment in the non-recurrent group. Peripheral blood analysis showed no significant differences in Neutrophil-Lymphocyte Ratio (NLR) and Lymphocyte-Monocyte Ratio (LMR). The results suggest a T cell-dominant immune response may prevent recurrence, while an MDSCs-dominant environment increases the risk. Changes in urinary T\/MDSCs, MDSCs\/Total Cell, and Neutrophil\/T cell ratios may serve as potential biomarkers for predicting recurrence risk shortly after induction therapy.<\/jats:p>","DOI":"10.1038\/s41598-025-14974-1","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:14:10Z","timestamp":1760087650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prediction of recurrence using hematologic and urinary markers in intravesical Bacillus calmette Guerin treated bladder cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-3451","authenticated-orcid":false,"given":"Mecit","family":"Celik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Emin","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Karaaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6ner","family":"Odabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Meric","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"14974_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: an overview. Int. J. Cancer. https:\/\/doi.org\/10.1002\/ijc.33588 (2021).","journal-title":"Int. J. Cancer"},{"key":"14974_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00428-015-1739-2","volume":"466","author":"E Comp\u00e9rat","year":"2015","unstructured":"Comp\u00e9rat, E. et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 466, 589\u2013594. https:\/\/doi.org\/10.1007\/s00428-015-1739-2 (2015).","journal-title":"Virchows Arch."},{"key":"14974_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/s0302-2838(02)00068-4","volume":"41","author":"M Brausi","year":"2002","unstructured":"Brausi, M. et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41, 523\u2013531. https:\/\/doi.org\/10.1016\/s0302-2838(02)00068-4 (2002).","journal-title":"Eur. Urol."},{"key":"14974_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier, S. et al. EORTC nomograms and risk groups for predicting recurrence, progression, and Disease-specific and overall survival in Non-Muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette-Gu\u00e9rin. Eur. Urol. 69, 60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045 (2016).","journal-title":"Eur. Urol."},{"key":"14974_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/mou.0000000000000741","volume":"30","author":"JA Witjes","year":"2020","unstructured":"Witjes, J. A. Developments in the follow-up of nonmuscle invasive bladder cancer: what did we learn in the last 24 months: a critical review. Curr. Opin. Urol. 30, 387\u2013391. https:\/\/doi.org\/10.1097\/mou.0000000000000741 (2020).","journal-title":"Curr. Opin. Urol."},{"key":"14974_CR6","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1172\/jci89717","volume":"127","author":"MF Chevalier","year":"2017","unstructured":"Chevalier, M. F. et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J. Clin. Invest. 127, 2916\u20132929. https:\/\/doi.org\/10.1172\/jci89717 (2017).","journal-title":"J. Clin. Invest."},{"key":"14974_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00345-016-1848-9","volume":"35","author":"MD Vartolomei","year":"2017","unstructured":"Vartolomei, M. D. et al. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J. Urol. 35, 121\u2013130. https:\/\/doi.org\/10.1007\/s00345-016-1848-9 (2017).","journal-title":"World J. Urol."},{"key":"14974_CR8","doi-asserted-by":"publisher","unstructured":"Patwardhan, M. V. & Mahendran, R. The bladder tumor microenvironment components that modulate the tumor and impact therapy. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms241512311 (2023).","DOI":"10.3390\/ijms241512311"},{"key":"14974_CR9","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1084\/jem.20181003","volume":"215","author":"YNS Wong","year":"2018","unstructured":"Wong, Y. N. S. et al. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. J. Exp. Med. 215, 2748\u20132759. https:\/\/doi.org\/10.1084\/jem.20181003 (2018).","journal-title":"J. Exp. Med."},{"key":"14974_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/s0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm, D. L. et al. Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol. 147, 596\u2013600. https:\/\/doi.org\/10.1016\/s0022-5347(17)37316-0 (1992).","journal-title":"J. Urol."},{"key":"14974_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3233\/blc-179018","volume":"3","author":"EM Messing","year":"2017","unstructured":"Messing, E. M., The, B. C. G. & Shortage Bladder Cancer 3, 227\u2013228, doi:https:\/\/doi.org\/10.3233\/blc-179018 (2017).","journal-title":"Bladder Cancer"},{"key":"14974_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","volume":"27","author":"SP Lerner","year":"2009","unstructured":"Lerner, S. P., Tangen, C. M., Sucharew, H., Wood, D. & Crawford, E. D. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol. Oncol. 27, 155\u2013159. https:\/\/doi.org\/10.1016\/j.urolonc.2007.11.033 (2009).","journal-title":"Urol. Oncol."},{"key":"14974_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"BP Schrier","year":"2004","unstructured":"Schrier, B. P., Hollander, M. P., van Rhijn, B. W., Kiemeney, L. A. & Witjes, J. A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur. Urol. 45, 292\u2013296. https:\/\/doi.org\/10.1016\/j.eururo.2003.10.006 (2004).","journal-title":"Eur. Urol."},{"key":"14974_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.37349\/etat.2024.00212","volume":"5","author":"E Jou","year":"2024","unstructured":"Jou, E., Chaudhury, N. & Nasim, F. Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment. Explor. Target. Antitumor Ther. 5, 187\u2013207. https:\/\/doi.org\/10.37349\/etat.2024.00212 (2024).","journal-title":"Explor. Target. Antitumor Ther."},{"key":"14974_CR15","doi-asserted-by":"publisher","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49 https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031 (2006). 466\u2009\u2013\u2009465; discussion 475\u2009\u2013\u2009467.","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"14974_CR16","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez, J. et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model. J. Urol. 182, 2195\u20132203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016 (2009).","journal-title":"J. Urol."},{"key":"14974_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester, R. J. et al. European association of urology (EAU) prognostic factor risk groups for Non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur. Urol. 79, 480\u2013488. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033 (2021).","journal-title":"Eur. Urol."},{"key":"14974_CR18","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/bjc.2013.372","volume":"109","author":"E Xylinas","year":"2013","unstructured":"Xylinas, E. et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br. J. Cancer. 109, 1460\u20131466. https:\/\/doi.org\/10.1038\/bjc.2013.372 (2013).","journal-title":"Br. J. Cancer"},{"key":"14974_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00261-013-0038-0","volume":"39","author":"HJ Wang","year":"2014","unstructured":"Wang, H. J. et al. Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection. Abdom. Imaging. 39, 135\u2013141. https:\/\/doi.org\/10.1007\/s00261-013-0038-0 (2014).","journal-title":"Abdom. Imaging"},{"key":"14974_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00259-016-3500-8","volume":"44","author":"P Alongi","year":"2017","unstructured":"Alongi, P. et al. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET\/CT. Eur. J. Nucl. Med. Mol. Imaging. 44, 224\u2013233. https:\/\/doi.org\/10.1007\/s00259-016-3500-8 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"14974_CR21","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.7314\/apjcp.2012.13.5.2229","volume":"13","author":"JX Chen","year":"2012","unstructured":"Chen, J. X. et al. A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac. J. Cancer Prev. 13, 2229\u20132234. https:\/\/doi.org\/10.7314\/apjcp.2012.13.5.2229 (2012).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"14974_CR22","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1038\/s41598-019-41844-4","volume":"9","author":"G Zhao","year":"2019","unstructured":"Zhao, G. et al. Glandular differentiation in pT1 urothelial carcinoma of bladder predicts poor prognosis. Sci. Rep. 9, 5323. https:\/\/doi.org\/10.1038\/s41598-019-41844-4 (2019).","journal-title":"Sci. Rep."},{"key":"14974_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00345-020-03188-x","volume":"39","author":"V Srougi","year":"2021","unstructured":"Srougi, V. et al. Prospective evaluation of a urinary biomarker panel to detect and predict recurrence of non-muscle-invasive bladder cancer. World J. Urol. 39, 453\u2013459. https:\/\/doi.org\/10.1007\/s00345-020-03188-x (2021).","journal-title":"World J. Urol."},{"key":"14974_CR24","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1158\/1055-9965.Epi-14-0035","volume":"23","author":"CJ Rosser","year":"2014","unstructured":"Rosser, C. J. et al. Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol. Biomarkers Prev. 23, 1340\u20131345. https:\/\/doi.org\/10.1158\/1055-9965.Epi-14-0035 (2014).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"14974_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"MD Shelley","year":"2001","unstructured":"Shelley, M. D. et al. A systematic review of intravesical Bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 88, 209\u2013216. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02306.x (2001).","journal-title":"BJU Int."},{"key":"14974_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.euf.2023.07.002","volume":"10","author":"T Yanagisawa","year":"2024","unstructured":"Yanagisawa, T. et al. Repeat transurethral resection for Non-muscle-invasive bladder cancer: an updated systematic review and Meta-analysis in the contemporary era. Eur. Urol. Focus. 10, 41\u201356. https:\/\/doi.org\/10.1016\/j.euf.2023.07.002 (2024).","journal-title":"Eur. Urol. Focus"},{"key":"14974_CR27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/iju.12572","volume":"21","author":"Y Kohjimoto","year":"2014","unstructured":"Kohjimoto, Y. et al. External validation of European organization for research and treatment of cancer and Spanish urological club for oncological treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin. Int. J. Urol. 21, 1201\u20131207. https:\/\/doi.org\/10.1111\/iju.12572 (2014).","journal-title":"Int. J. Urol."},{"key":"14974_CR28","doi-asserted-by":"publisher","first-page":"655000","DOI":"10.3389\/fonc.2021.655000","volume":"11","author":"M Adamkiewicz","year":"2021","unstructured":"Adamkiewicz, M. et al. Lymphocyte-to-Monocyte ratio is the independent prognostic marker of progression in patients undergoing BCG-Immunotherapy for bladder cancer. Front. Oncol. 11, 655000. https:\/\/doi.org\/10.3389\/fonc.2021.655000 (2021).","journal-title":"Front. Oncol."},{"key":"14974_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.euo.2018.06.006","volume":"1","author":"F Cantiello","year":"2018","unstructured":"Cantiello, F. et al. Systemic inflammatory markers and oncologic outcomes in patients with High-risk Non\u2013muscle-invasive urothelial bladder cancer. Eur. Urol. Oncol. 1, 403\u2013410. https:\/\/doi.org\/10.1016\/j.euo.2018.06.006 (2018).","journal-title":"Eur. Urol. Oncol."},{"key":"14974_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 41, 374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016 (2023).","journal-title":"Cancer Cell."},{"key":"14974_CR31","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson, N. M. & Simon, M. C. The tumor microenvironment. Curr. Biol. 30, R921\u2013r925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081 (2020).","journal-title":"Curr. Biol."},{"key":"14974_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/imr.13142","volume":"314","author":"L Kalafati","year":"2023","unstructured":"Kalafati, L., Hatzioannou, A., Hajishengallis, G. & Chavakis, T. The role of neutrophils in trained immunity. Immunol. Rev. 314, 142\u2013157. https:\/\/doi.org\/10.1111\/imr.13142 (2023).","journal-title":"Immunol. Rev."},{"key":"14974_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668. https:\/\/doi.org\/10.1038\/s41577-020-0306-5 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"14974_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","volume":"17","author":"NR Maimela","year":"2019","unstructured":"Maimela, N. R., Liu, S. & Zhang, Y. Fates of CD8\u2009+\u2009T cells in tumor microenvironment. Comput. Struct. Biotechnol. J. 17, 1\u201313. https:\/\/doi.org\/10.1016\/j.csbj.2018.11.004 (2019).","journal-title":"Comput. Struct. Biotechnol. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14974-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14974-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14974-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:14:10Z","timestamp":1760087650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14974-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14974"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14974-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All co-authors agreed to publication of the acquired data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35415"}}